Drugs / 18F-CP6A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06827821 | Feb 2025 → Dec 2026 expected | synucleinopathy | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-CP6A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06827821 ↗ |
| Modality | Diagnostic / imaging agent | “The 18F-labeled probe of CP6A preferentially highlights α-Syn deposition in the brains of animal models” NCT06827821 ↗ |
| Route | Intravenous | “Evaluate the safety of a single intravenous dose of 18F-CP6A in participants.” NCT06827821 ↗ |